Clinical Trials@2x
  • News

    Most Read

    • Lilly’s bamlanivimab prevents Covid-19 at nursing homes in BLAZE-2 trial
    • Moderna begins dosing in Covid-19 vaccine study in Japan
    • Reify Health extends StudyTeam platform availability for clinical trials

    Most Recent

    Clinical Trials

    Lilly’s bamlanivimab prevents Covid-19 at nursing homes in BLAZE-2 trial

    22 Jan 2021
  • Analysis

    Sections

    • Features
    • Comment
    • Projects

    Most Read

    • Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy
    • Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market
    • Novo Nordisk’s makes strides into Alzheimer’s with anti-diabetic drug

    Most Recent

    Clinical Trials

    Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy

    12 Jan 2021
  • Sectors

    Sections

    • Clinical Trials
    • Approvals
    • Clinical Research
    • Operations
    • Outsourcing
    • Supply Chain
    • Cold Chain
    • Data Management
    • Medical Devices

    Most Read

    • Global clinical trials activity increases 14.0oY in Q4 2020
    • Total number of Covid-19 clinical trials continues to rise as cases and deaths rise
    • Orphazyme’s arimoclomol expected to be used with Zavesca after likely FDA approval in Niemann-Pick disease type C

    Most Recent

    Global clinical trials activity increases 14.0oY in Q4 2020

    22 Jan 2021
  • Themes
  • Deals

    Most Read

    • Investment firm GI Partners closes Clinical Ink acquisition
    • Investment firm GI Partners to acquire minority interest in Clinical Ink
    • IVI and SNU partner to trial Inovio’s Covid-19 vaccine in Korea

    Most Recent

    Clinical Trials

    Investment firm GI Partners closes Clinical Ink acquisition

    27 Aug 2020
  • Companies

    Sections

    • Company A-Z
    • Company Categories
    • Products & Services
    • Company Releases
    • White Papers
    • Videos

    Most Read

    • Linari NanoTech
    • OpenClinica
    • Strategikon Pharma

    Most Recent

    Linari NanoTech

    19 Jan 2021
  • Magazine
  • Events
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Approvals
    • Clinical Research
    • Operations
    • Outsourcing
    • Supply Chain
    • Cold Chain
    • Data Management
    • Medical Devices
  • Deals
  • Tech
  • Disruption
  • Coronavirus
Partners
  • Accelerating Clinical Trials
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register
How to Source Non-IMP Supplies for Clinical Trials

How to Source Non-IMP Supplies for Clinical Trials

Tim Holmes, Manager, Clinical Oversight of Supplies, Biogen, offers considerations on how to obtain non-IMP...

11th February 2019
Sandoz Abandons US Development of Rixathon

Sandoz Abandons US Development of Rixathon

Chloé Thépaut, MRes, Oncology Senior Analyst, GlobalData, examines the implications of Sandoz’s abandoned attempt to...

6th February 2019
GDPR: The Implications for Clinical Development

GDPR: The Implications for Clinical Development

Eight months in, Nigel Hughes, Scientific Director JCI-PDR, Janssen, examines the ramifications of GDPR on...

4th February 2019
Industry Viewpoints: Patient Recruitment and Expanded Access

Industry Viewpoints: Patient Recruitment and Expanded Access

In the latest Industry Viewpoint, Howard Fingert speaks to CTA’s Elizabeth Williams about the challenges...

30th January 2019
Medical Device Development – Challenges of an SME

Medical Device Development – Challenges of an SME

John Shillingford, Clinical Operations Director, Orsus Medical, describes the inherent challenges facing small- to mid-sized...

28th January 2019
MDMA Treatments Found to Eliminate PTSD Symptoms in Phase II Trial

MDMA Treatments Found to Eliminate PTSD Symptoms in Phase II Trial

Gavin Davidson, CVMD Analyst, GlobalData, examines how MDMA is used to treat patients with PTSD

23rd January 2019
How Whole Systems Thinking Could Transform the Clinical Supply Chain

How Whole Systems Thinking Could Transform the Clinical Supply Chain

Hedley Rees, Chief Disruptor, PharmaFlow, discusses the need for a rethink on supply chain processes

21st January 2019
Managing Blinding Requirements in IRT: An Overview

Managing Blinding Requirements in IRT: An Overview

Francesco Spoto, Clinical Project Manager, explores the opportunities of using IRT solutions to manage blinded...

18th January 2019
Integrating New Assets: A Supply Chain Perspective

Integrating New Assets: A Supply Chain Perspective

Barrett Glasser, Associate Director, Clinical Drug Supply, Biogen, provides an overview on how to on...

14th January 2019
Observations from GCP Sponsor Inspections

Observations from GCP Sponsor Inspections

Kevin Anderson, Director, Global Clinical Operations, Alexion Pharmaceuticals, offers a perspective on what he has...

11th January 2019

Latest News

Clinical Trials

Lilly’s bamlanivimab prevents Covid-19 at nursing homes in BLAZE-2 trial

22 Jan 2021
Clinical Trials

Moderna begins dosing in Covid-19 vaccine study in Japan

22 Jan 2021
Clinical Research

Reify Health extends StudyTeam platform availability for clinical trials

21 Jan 2021
Clinical Trials

Forma doses first patient in Phase I prostate cancer treatment trial

21 Jan 2021

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
Clinical Trials

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms and Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more